

REFERENCES

1. Weinberger M, Hendeles L. Theophylline in asthma. *N Engl J Med* 1996; 334 (21):1380-1388.
2. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? *Eur Respir J* 1994; 7(3):579-591.
3. Stoloff SW. The changing role of theophylline in pediatric asthma. *Am Fam Physician* 1994; 49(4):839-844.
4. Kraft M, Torvik JA, Trudeau JB, Wenzel SE, Martin RJ. Theophylline: potential antiinflammatory effects in nocturnal asthma. *J Allergy Clin Immunol* 1996; 97(6):1242-1246.
5. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. *Eur Respir J* 1995; 8(6):996-1000.
6. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. *Am J Respir Crit Care Med* 1995; 151(6):1907-1914.
7. Blake K, Kamada AK. Asthma. Theophylline. In: Herfindal ET, Gourley DR, eds. *Textbook of Therapeutics: Drug and Disease Management*. 6th ed. Maryland: William & Wilkins, 1996: 662-669.
8. Hill NS. The use of theophylline in 'irreversible' chronic obstructive pulmonary disease. An update. *Arch Intern Med* 1988; 148(12):2579-2584.

9. Boushey HA. Drugs Used in Asthma. In: Katzung BG, ed. Basic & Clinical Pharmacology. 8th ed. New York: The McGraw-Hill Companies, Inc., 2001: 333-349.
10. Winter ME. Theophylline. In: Koda-Kimber MA, ed. Basic Clinical Pharmacology. 3rd ed. Washington: Applied Therapeutics, Inc., 1994: 405-412.
11. Hendeles L, Weinberger M. Theophylline product and dosing interval selection for chronic asthma. *J Allergy Clin Immunol* 1985; 76(2 Pt 2):285-291.
12. Weinberger M, Hendeles L, Bighley L. The relation of product formulation to absorption of oral theophylline. *N Engl J Med* 1978; 299(16):852-857.
13. Weinberger MM. Theophylline QID, TID, BID and now OD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24. *Pharmacotherapy* 1984; 4(4):181-198.
14. Gonzalez MA, Kisicki J, Straughn AB. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system. *Clin Ther* 1994; 16(4):686-692.
15. Berkowitz RB, Tinkelman DG, Marcoux JP, Rooklin AR, Zeitz HJ, Rennard SI et al. Conversion from twice- to once-daily extended-release theophylline treatment in patients with reversible airway obstruction. *J Asthma* 1995; 32(4):275-284.
16. Tanigawara Y, Komada F, Shimizu T, Iwakawa S, Iwai T, Maekawa H et al. Population pharmacokinetics of theophylline. III. Premarketing study for a once-daily administered preparation. *Biol Pharm Bull* 1995; 18(11):1590-1598.

17. Edwards TB, Dockhorn RJ, Wagner DE, Fiddes RA, Grossman J, Menendez R et al. Efficacy of once daily extended-release theophylline in decreasing the use of inhaled beta 2-agonists in stable, mild-to-moderate asthma patients. *Ann Allergy Asthma Immunol* 1995; 75(5):409-416.
18. Gonzalez MA, Straughan AB. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. *Clin Ther* 1994; 16(5):804-814.
19. Gai MN, Thielemann AM, Arancibia A. Evaluation of the effect of different kinds of foods on the bioavailability of a sustained-release theophylline tablet. *Int J Clin Pharmacol Ther Toxicol* 1993; 31(11):547-552.
20. Karim A. Effects of food on the bioavailability of theophylline from controlled-release products in adults. *J Allergy Clin Immunol* 1986; 78(4 Pt 2):695-703.
21. Lagas M, Jonkman JH. Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences. *Pharm Weekly [Sci]* 1985; 7(1):10-14.
22. Harrison LI, Kehe CR, Ekholm BP, Chang SF, Lavoie KA, Kisicki JC. Comparative pharmacokinetics of morning and evening doses of once-a-day theophylline capsules. *J Pharm Sci* 1994; 83(8):1171-1174.
23. Kanthawatana S, Tontayapiwat A, Tonsuwannont W, Manorot M. A single-dose comparison of three slow-release theophylline oral preparations in healthy Thai volunteers. *Asian Pac J Allergy Immunol* 1996; 14(1):13-18.

24. Oosterhuis B, Brannan MD, Groen H, Peeters PA, Hempenius J, Radwanski E et al. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur). *Ann Allergy Asthma Immunol* 1995; 75(2):157-161.
25. Nagata K, Ishitobi K, Yamamoto Y, Ikeda T, Hori S, Matsumoto Y et al. Increased theophylline metabolism in the menstrual phase of healthy women. *J Allergy Clin Immunol* 1997; 100(1):39-43.
26. Riegelman S, Jenne JW. Controlled release theophylline [editorial]. *Chest* 1980; 78(2):250-251.
27. Weinberger MM, Bronsky EA. Evaluation of oral bronchodilator therapy in asthmatic children. *Bronchodilators in asthmatic children. J Pediatr* 1974; 84(3):421-427.
28. Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ. Interaction of ephedrine and theophylline. *Clin Pharmacol Ther* 1975; 17(5):585-592.
29. Jenne JW, Wyze MS, Rood FS, MacDonald FM. Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. *Clin Pharmacol Ther* 1972; 13(3):349-360.
30. Jacobs MH, Senior RM, Kessler G. Clinical experience with theophylline. Relationships between dosage, serum concentration, and toxicity. *JAMA* 1976; 235(18):1983-1986.
31. Welsh PW, Reed CE, Conrad E. Timing of once-a-day theophylline dose to match peak blood level with diurnal variation in severity of asthma. *Am J Med* 1986; 80(6):1098-1102.

32. Arkinstall WW, Atkins ME, Harrison D, Stewart JH. Once-daily sustained-release theophylline reduces diurnal variation in spirometry and symptomatology in adult asthmatics. *Am Rev Respir Dis* 1987; 135(2):316-321.
33. Bertino JS Jr. Theophylline. In: Schumacher GE, ed. *Therapeutic drug monitoring*. Appleton & Lange: Norwalk, Connecticut, 1995: 553-586.
34. Physicians' Desk reference. 52th ed. Montvale, NJ: Medical Economics Company Inc., 1998.
35. Edwards DJ, Zarowitz BJ, Slaughter RL. Theophylline. In: Evan WE, Schentag JJ, Jusko WJ, eds. *Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring*. 1992: 13-1-13-29.
36. Hill MR, Kamada AK. Pathogenesis of asthma: therapeutic implications. *The Annals of Pharmacotherapy* 1991; 25(9):993-1001.
37. Costello J. Asthma--the problem and the paradox. *Postgrad Med J* 1991; 67 Suppl 4:S1-S5.
38. Page CP. Are mast cells all bad? *Postgrad Med J* 1991; 67 Suppl 4:S6-11.
39. Bush RK. Nocturnal asthma: mechanisms and the role of theophylline in treatment. *Postgrad Med J* 1991; 67 Suppl 4:S20-S24.
40. Barnes P, FitzGerald G, Brown M, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. *N Engl J Med* 1980; 303 (5):263-267.
41. Douglas NJ. Asthma at night. *Clin Chest Med* 1985; 6(4):663-674.

42. Busse WW. Pathogenesis and pathophysiology of nocturnal asthma. Am J Med 1988; 85(1B):24-29.
43. Abbott Laboratory. TDx System Operator's Guide. Irving, Texas: 1985.
44. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62(1-2):41-55.